(Q46979548)

27 December 2017

title

Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome (English)

1 reference

27 December 2017

polycystic ovary syndrome

main subject

obesity

0 references

1 reference

1 reference

1 reference

Alessandro D Genazzani

object named as

Alessandro D Genazzani

1

0 references

author name string

Claudia Strucchi

2

1 reference

27 December 2017

Michele Luisi

3

1 reference

27 December 2017

Elena Casarosa

4

1 reference

27 December 2017

Chiara Lanzoni

5

1 reference

27 December 2017

Enrica Baraldi

6

1 reference

27 December 2017

Federica Ricchieri

7

1 reference

27 December 2017

Hilda Mehmeti

8

1 reference

27 December 2017

Andrea R Genazzani

9

1 reference

27 December 2017

publication date

1 January 2006

1 reference

27 December 2017

Gynecological Endocrinology

published in

1 reference

27 December 2017

volume

22

1 reference

27 December 2017

issue

1

1 reference

27 December 2017

page(s)

36-43

1 reference

27 December 2017

Adrenocortical hyperresponsiveness to corticotropin in polycystic ovary syndrome patients with adrenal androgen excess

cites work

1 reference

https://api.crossref.org/works/10.1080%2F09513590500476164

Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500476164

Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500476164

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500476164

Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500476164

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500476164

Dexamethasone reduces androgen levels in metformin-treated patients with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500476164

Neurosteroids: a new brain function?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500476164

Neurosteroid biosynthesis: genes for adrenal steroidogenic enzymes are expressed in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500476164

Neurosteroids Biosynthesis and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500476164

Pulsatile secretory characteristics of allopregnanolone, a neuroactive steroid, during the menstrual cycle and in amenorrheic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500476164

Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500476164

Luteinizing hormone (LH) secretory burst duration is independent from LH, prolactin, or gonadal steroid plasma levels in amenorrheic women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500476164

Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500476164

Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500476164

Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500476164

Metformin treatment reduces ovarian cytochrome P-450c17alpha response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500476164

Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500476164

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500476164

Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500476164

Glucose action and adrenocortical biosynthesis in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500476164

How common are polycystic ovaries in normal women and what is their significance for the fertility of the population?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500476164

A long-term treatment with gonadotropin-releasing hormone agonist plus a low-dose oral contraceptive improves the recovery of the ovulatory function in patients with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500476164

The use of a combined regimen of GnRH agonist plus a low-dose oral contraceptive improves the spontaneous pulsatile LH secretory characteristics in patients with polycycstic ovary disease after discontinuation of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09513590500476164

10.1080/09513590500476164

21 January 2018

Identifiers

DOI

1 reference

27 December 2017

PubMed ID

16522532

1 reference

27 December 2017